BioFluidica has appointed Rolf Muller as CEO. He will assume responsibilities immediately and will succeed Steven Soper, who will remain the company’s chief technology officer. BioFluidica develops technologies for the isolation and analysis of rare, circulating biomarkers in the blood. The company's first platform is being used analyze liquid biopsies to isolate circulating tumor cells and other rare cells from the blood. Prior to joining BioFluidica, Muller was the cofounder and president of Biomatrica.